Bloom Standard wins $50K pediatric medtech grant at MPDC Showcase
What's the deal? The Midwest Pediatric Device Consortium (MPDC) awarded $200,000 in non-dilutive grants to four startups building cardiovascular devices for children. Each company received $50,000 at the consortium's 2026 Showcase in Cincinnati, held in collaboration with the Alliance for Pediatric Device Innovation (APDI) and the Advanced Cardiac Therapies Improving Outcomes Network (ACTION).
The winners: Bloom StandardDealroom has a profile for this one. Try Dealroom → is developing the RAPIDscan Ultrasound System for early detection of heart and lung abnormalities. AcQumen MedicalDealroom has a profile for this one. Try Dealroom → is building a needle-free, catheter-free blood-flow monitoring device. The Edelman Lab at the Harvard-MIT Biomedical Engineering Center is working on a polymeric stent for children with congenital heart defects. PolyVascularDealroom has a profile for this one. Try Dealroom → is creating a polymer-based pulmonary valve designed to grow with the child, reducing repeat open-heart surgeries.
Why now? About 40,000 babies in the US are born with a heart defect each year, according to the CDC — yet paediatric device companies receive less than 2% of seed funding in the healthtech sector. Children represent 22% of the US population but remain badly underserved by traditional medtech pipelines.
Several founders are motivated by personal experience. Bloom Standard chief executive Annamarie Saarinen's newborn daughter was diagnosed with heart failure. "Minutes and hours matter with these kids," she said. PolyVascular's Katie Bales learned of her son's congenital heart defect prenatally and was told there were "no great options." AcQumen founder Dori Jones was driven by her son's time in the NICU and paediatric ICU.
What could go wrong? Paediatric medical devices face uniquely steep regulatory and commercial hurdles. Patient populations are small, clinical trials harder to run, and evidence requirements demanding. "The pediatric cardiovascular space is specialised, the evidence requirements are challenging, but the impact can be enormous," said Cory Criss, a paediatric surgeon at Nationwide Children's Hospital and MPDC co-lead.
At $50,000 per award, the grants are modest — enough to push early-stage work forward but far short of what full device development and regulatory clearance demand.
The signal: Both Bloom Standard and AcQumen Medical are classified as early-stage companies on Dealroom, underscoring how nascent the paediatric cardiovascular device space remains. With less than 2% of healthtech seed funding reaching child-focused device makers, consortia like MPDC are functioning less as accelerators and more as primary capital sources — a sign that commercial investors have yet to price in a patient population of 40,000 new cases per year.
Read more: einpresswire.com
